MEKhANIZM DEYSTVIYa I KLINIChESKOE PRIMENENIE METFORMINA (SIOFOR®): OBZOR LITERATURY
- Authors: Demidova IY.1, Gorokhova TV1
-
Affiliations:
- Issue: No 17 (2009)
- Pages: 10-15
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278085
- ID: 278085
Cite item
Full Text
Abstract
Рассмотрены история создания и механизмы сахароснижающего действия метформина (Сиофор). Представлены данные о применении метформина с целью профилактики сахарного диабета типа 2, его влиянии на факторы риска сердечно-сосудистых заболеваний. Обсуждаются возможности использования метформина вне лечения сахарного диабета типа 2 (атеросклероз, неалкогольный жировой гепатоз, синдром поликистозных яичников). Рассматриваются побочные явления, связанные с применением метформина.
References
- Балаболкин М.И., Креминская В.М. Эффективность и место сиофора (метформина) в терапии сахарного диабета 2 типа // Сахарный диабет. 2001. № 1. С. 1-10.
- Schafer G. Biguanides - a review of history, pharmacodynamics and therapy. Diab Metab (Paris) 1983;9:148-65.
- Misbin RI, Green I, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265-66.
- U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS ). Lancet 1998;352:837-53.
- Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 1999;58(Suppl.):31-39.
- Wu MS, Johnston P, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990;13:1-8.
- Kozka IJ, Holman GD. Metformin blocks down-regulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes. Diabetes 1993;42:1159-65.
- Matthaei S, Reibold JP, Hamann A, et al. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rataadipocytes. Endocrinology 1993;133:304-11.
- Сuyton AC. Textbook of Medical Physiology. W.B. Saunders Co 7th Edition, 1986.
- Prager R, Shernthaner G, Graf H. Effect of metformin on peripheral inulin sensitivity in non insulin dependent diabetes mellitus. Diabete Metab 1986;12(6):346-50.
- Althoff PH, Haupt E, Pichel C. Metformin increases insulin sensitivity and first phase of the arginin - induced insulin response in type 2 diabetes. Diabetes 1991;40(Suppl. 1):342.
- Argaud D, Roth H, Wiemspreger N. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. Eur J Biochem 1993;213:1341-48.
- Signore A, Fiore V, Chianelli M, et al. The effect of Metformin on Liver Blood-Flow in Vivo in Normal Subjects with Non-Insulin Dependent Diabetes. Diab Res Clin Pract 1996;33(2):83-87.
- Zou MH, Wu Y. AMP-activated proteine kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol 2008;35:535-45.
- Cuthbertson J, Patterson S, Bell PM. Metformin combined with exogenous glucagons-like peptide-1 gives added benefit by improving acute glycemic control in type 2 diabetic subjects. European Association for the study of Diabetes 2008:378, abstr.
- Bailey CJ. Metformin - an update. Gen Pharmacol 1993;24:1299-309.
- DeFronzo RA, Goodman AM. The Metformin Investigator Group: Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1995;333:541-49.
- Tessari P, Tiengo A. Metformin treatment of rats with diet-induced overweight and hypertriglyceridemia decreases plasma triglyceride concentrations, while decreasing triglyceride and increasing ketone body output by the isolated perfused liver. Acta Diabetol 2008;21.
- Ohira M, Miyashita Y, Ebisuno M, et al. Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. Diabetes Res Clin Pract 2007;78(1):34-41.
- Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003,29:6S44-52
- Collier A, Watson HK, Patrick AW, et al. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin - dependent) diabetic patients. Diabetes Metab 1989;15(6):420-25.
- Makimattila S, Nikkila, K, Yki-Harvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 1999;42:406-12.
- Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993;44:107-12.
- Morin-Papunen L, Rautio K. Metformin reduces serum C - reactive proteine levels in women with polycystic ovary syndrome. J Clin Endicrinol Metab 2003;88(10):4649-54.
- Schurman L, McCarthy AD, Sedlinsky C, et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 2008;116(6):333-40.
- Skrha J, Kvasnicka J, Zima T Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus. Eur J Clin Pharmacol 2007;63(12):1107-14.
- Meaney E, Vela A, Samaniego V. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: The Mefisto Study. J Clin Exp Pharmacol Physiol 2008;35(8):895-903.
- Chen SQ, Liu Q, Sun H, et al. Effects of metformin on fatty liver in insulin-resistant rats. Zhondhua Gan Zang Bing Za Zhi 2005;13(12):915-18.
- Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications 2007;21(3):137-42.
- Сreangaa AA, Bradley HM, McCormick C, et al. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol 2008;111(4):959-68.
- Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfaftl lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;25(1):CD002967.
- Kamber N, Davis WA, Bruce DG, et al. Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study. Med J Aust 2008;21(8):446-49.
- Ting RZ, Szeto CC, Chan MH, et al. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med 2006;9(166):1975-79.